---
document_datetime: 2025-12-02 06:50:25
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/alpivab.html
document_name: alpivab.html
version: success
processing_time: 0.1064232
conversion_datetime: 2025-12-28 00:09:59.931682
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Alpivab

[RSS](/en/individual-human-medicine.xml/66481)

##### Withdrawn

This medicine's authorisation has been withdrawn

peramivir Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Alpivab](#news-on)
- [More information on Alpivab](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 20 November 2020, the European Commission withdrew the marketing authorisation for Alpivab (peramivir) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, BioCryst Ireland Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Alpivab was granted a marketing authorisation in the EU on 13 April 2018 for the treatment of uncomplicated influenza in adults and children from the age of 2 years. The marketing authorisation was valid for a 5-year period. The product had not been marketed in the EU.

The European Public Assessment Report (EPAR) for Alpivab is updated to indicate that the marketing authorisation is no longer valid.

Alpivab : EPAR - Medicine overview

Reference Number: EMEA/H/C/004299

English (EN) (650.2 KB - PDF)

**First published:** 25/04/2018

**Last updated:** 09/12/2020

[View](/en/documents/overview/alpivab-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-520)

български (BG) (1.27 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/bg/documents/overview/alpivab-epar-medicine-overview_bg.pdf)

español (ES) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/es/documents/overview/alpivab-epar-medicine-overview_es.pdf)

čeština (CS) (1.26 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/cs/documents/overview/alpivab-epar-medicine-overview_cs.pdf)

dansk (DA) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/da/documents/overview/alpivab-epar-medicine-overview_da.pdf)

Deutsch (DE) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/de/documents/overview/alpivab-epar-medicine-overview_de.pdf)

eesti keel (ET) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/et/documents/overview/alpivab-epar-medicine-overview_et.pdf)

ελληνικά (EL) (1.28 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/el/documents/overview/alpivab-epar-medicine-overview_el.pdf)

français (FR) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/fr/documents/overview/alpivab-epar-medicine-overview_fr.pdf)

hrvatski (HR) (1.22 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/hr/documents/overview/alpivab-epar-medicine-overview_hr.pdf)

italiano (IT) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/it/documents/overview/alpivab-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (1.26 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/lv/documents/overview/alpivab-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (1.22 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/lt/documents/overview/alpivab-epar-medicine-overview_lt.pdf)

magyar (HU) (1.25 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/hu/documents/overview/alpivab-epar-medicine-overview_hu.pdf)

Malti (MT) (1.26 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/mt/documents/overview/alpivab-epar-medicine-overview_mt.pdf)

Nederlands (NL) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/nl/documents/overview/alpivab-epar-medicine-overview_nl.pdf)

polski (PL) (1.25 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/pl/documents/overview/alpivab-epar-medicine-overview_pl.pdf)

português (PT) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/pt/documents/overview/alpivab-epar-medicine-overview_pt.pdf)

română (RO) (1.22 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/ro/documents/overview/alpivab-epar-medicine-overview_ro.pdf)

slovenčina (SK) (1.26 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/sk/documents/overview/alpivab-epar-medicine-overview_sk.pdf)

slovenščina (SL) (1.25 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/sl/documents/overview/alpivab-epar-medicine-overview_sl.pdf)

Suomi (FI) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/fi/documents/overview/alpivab-epar-medicine-overview_fi.pdf)

svenska (SV) (1.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/sv/documents/overview/alpivab-epar-medicine-overview_sv.pdf)

## Product information

Alpivab : EPAR - Product Information

English (EN) (1.57 MB - PDF)

**First published:** 25/04/2018

**Last updated:** 09/12/2020

[View](/en/documents/product-information/alpivab-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-393)

български (BG) (3.2 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/bg/documents/product-information/alpivab-epar-product-information_bg.pdf)

español (ES) (2.3 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/es/documents/product-information/alpivab-epar-product-information_es.pdf)

čeština (CS) (2.77 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/cs/documents/product-information/alpivab-epar-product-information_cs.pdf)

dansk (DA) (2.25 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/da/documents/product-information/alpivab-epar-product-information_da.pdf)

Deutsch (DE) (2.3 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/de/documents/product-information/alpivab-epar-product-information_de.pdf)

eesti keel (ET) (2.23 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/et/documents/product-information/alpivab-epar-product-information_et.pdf)

ελληνικά (EL) (3.21 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/el/documents/product-information/alpivab-epar-product-information_el.pdf)

français (FR) (2.29 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/fr/documents/product-information/alpivab-epar-product-information_fr.pdf)

hrvatski (HR) (2.31 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/hr/documents/product-information/alpivab-epar-product-information_hr.pdf)

íslenska (IS) (2.25 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/is/documents/product-information/alpivab-epar-product-information_is.pdf)

italiano (IT) (2.28 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/it/documents/product-information/alpivab-epar-product-information_it.pdf)

latviešu valoda (LV) (2.89 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/lv/documents/product-information/alpivab-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.37 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/lt/documents/product-information/alpivab-epar-product-information_lt.pdf)

magyar (HU) (2.75 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/hu/documents/product-information/alpivab-epar-product-information_hu.pdf)

Malti (MT) (2.78 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/mt/documents/product-information/alpivab-epar-product-information_mt.pdf)

Nederlands (NL) (2.27 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/nl/documents/product-information/alpivab-epar-product-information_nl.pdf)

norsk (NO) (2.24 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/no/documents/product-information/alpivab-epar-product-information_no.pdf)

polski (PL) (2.84 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/pl/documents/product-information/alpivab-epar-product-information_pl.pdf)

português (PT) (2.28 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/pt/documents/product-information/alpivab-epar-product-information_pt.pdf)

română (RO) (2.4 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/ro/documents/product-information/alpivab-epar-product-information_ro.pdf)

slovenčina (SK) (2.76 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/sk/documents/product-information/alpivab-epar-product-information_sk.pdf)

slovenščina (SL) (2.71 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/sl/documents/product-information/alpivab-epar-product-information_sl.pdf)

Suomi (FI) (2.25 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/fi/documents/product-information/alpivab-epar-product-information_fi.pdf)

svenska (SV) (2.26 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/sv/documents/product-information/alpivab-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0004 20/11/2020

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Alpivab : EPAR - All Authorised presentations

English (EN) (581.31 KB - PDF)

**First published:** 25/04/2018

**Last updated:** 09/12/2020

[View](/en/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-60)

български (BG) (1.17 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/bg/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_bg.pdf)

español (ES) (1.13 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/es/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_es.pdf)

čeština (CS) (1.15 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/cs/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (1.12 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/da/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (1.12 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/de/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (1.12 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/et/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (1.17 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/el/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_el.pdf)

français (FR) (1.12 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/fr/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (1.14 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/hr/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (1.13 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/is/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_is.pdf)

italiano (IT) (1.12 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/it/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (1.16 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/lv/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (1.14 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/lt/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (1.15 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/hu/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (1.16 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/mt/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (1.13 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/nl/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (1.12 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/no/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_no.pdf)

polski (PL) (1.16 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/pl/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_pl.pdf)

português (PT) (1.13 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/pt/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_pt.pdf)

română (RO) (1.14 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/ro/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (1.16 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/sk/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (1.15 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/sl/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (1.12 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/fi/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (1.13 MB - PDF)

**First published:**

25/04/2018

**Last updated:**

09/12/2020

[View](/sv/documents/all-authorised-presentations/alpivab-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Alpivab Active substance peramivir International non-proprietary name (INN) or common name peramivir Therapeutic area (MeSH) Influenza, Human Anatomical therapeutic chemical (ATC) code J05AH03

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Alpivab is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years.

## Authorisation details

EMA product number EMEA/H/C/004299 Marketing authorisation holder

Biocryst

Biocryst

Marketing authorisation issued 13/04/2018 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Alpivab : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.2 MB - PDF)

**First published:** 12/06/2019

**Last updated:** 09/12/2020

[View](/en/documents/procedural-steps-after/alpivab-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Alpivab : EPAR - Public assessment report

Reference Number: EMA/CHMP/148367/2018

English (EN) (6.34 MB - PDF)

**First published:** 25/04/2018

**Last updated:** 09/12/2020

[View](/en/documents/assessment-report/alpivab-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Alpivab

Adopted

Reference Number: EMA/CHMP/97060/2018

English (EN) (623.37 KB - PDF)

**First published:** 23/02/2018

**Last updated:** 09/12/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-alpivab_en.pdf)

#### News on Alpivab

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-february-2018) 23/02/2018

#### More information on Alpivab

- [EMEA-001856-PIP02-16-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001856-pip02-16-m02)

**This page was last updated on** 09/12/2020

## Share this page

[Back to top](#main-content)